Shares of Clearside Biomedical CLSD were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 15.38% over the past year to ($0.11), which beat the estimate of ($0.12).
Revenue of $780,000 up by 120.34% year over year, which beat the estimate of $690,000.
Looking Ahead
Clearside Biomedical hasn't issued any earnings guidance for the time being.
Clearside Biomedical hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 10, 2021
Time: 04:30 PM
ET Webcast URL: https://ir.clearsidebio.com/events-and-presentations
Recent Stock Performance
52-week high: $7.29
Company's 52-week low was at $1.25
Price action over last quarter: Up 107.56%
Company Profile
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
